Sheng Cui

This inventor holds 19 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Amgen Inc., Cytokinetics, Inc., Newamsterdam Pharma B.v.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sheng Cui. Retrieved from https://idiyas.com/inventor/sheng-cui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 14)

% Patents Active = 89.5

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 76(Granted Patents)

Location History:

Camarillo, CA (US) (2013)
Lexington, MA (US) (2018 - 2024)
Thousand Oaks, CA (US) (2022 - 2024)

Company Filing History:

Newamsterdam Pharma B.v.

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Methylation

Omecamtiv Mecarbil

Pharmaceutical Salts

Macrocyclic Inhibitors

Vinyl Cyclobutyl

Thiazolones

Crystal Forms

Synthesis Processes

AMG 416

Intermediates

Asymmetric Process

Compound Synthesis

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741977 - Methylation of Mcl-1 compounds (2026-09-22),

2. 12623993 - Synthesis of vinyl cyclobutyl intermediates (2026-05-12),

3. 12612366 - Salts and crystal forms of omecamtiv mecarbil (2026-04-28),

4. 12583821 - Salt of omecamtiv mecarbil and process for preparing salt (2026-03-24),

5. 12570628 - Salts of obicetrapib and processes for their manufacture and intermediates thereof (2026-03-10),

6. 12441741 - Ring closing synthesis of macrocyclic MCL-1 inhibitor intermediates (2025-10-14),

7. 12378221 - Salts of obicetrapib and processes for their manufacture and intermediates thereof (2025-08-05),

8. 12221417 - Salt of omecamtiv mecarbil and process for preparing salt (2025-02-11),

9. 12006305 - Salts of obicetrapib and processes for their manufacture and intermediates thereof (2024-06-11),

10. 11958809 - Salt of omecamtiv mecarbil and process for preparing salt (2024-04-16),

11. 11926592 - Salts and crystal forms of omecamtiv mecarbil (2024-03-12),

12. 11708341 - Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof (2023-07-25),

13. 11472773 - Salt of omecamtiv mecarbil and process for preparing salt (2022-10-18),

14. 11465969 - Salts and crystal forms of omecamtiv mecarbil (2022-10-11),

15. 11377474 - Method for preparing AMG 416 (etelcalcetide) (2022-07-05),

Title: **Innovations of Sheng Cui: A Trailblazer in Pharmaceutical Patents**

Introduction

Sheng Cui, located in Lexington, MA, has made significant contributions to the pharmaceutical field, evidenced by his impressive portfolio of 12 patents. His innovative work primarily focuses on the development of pharmaceutical compounds and their formulations, addressing critical needs in medicine.

Latest Patents

Among Sheng Cui's latest innovations are two notable patents:

1. **Salt of Omecamtiv Mecarbil and Process for Preparing Salt**: This patent includes the dihydrochloride salt forms of omecamtiv mecarbil, along with compositions and pharmaceutical formulations. It also elaborates on methods for their preparation and application in therapeutic settings.

2. **Salts of Obicetrapib and Processes for Their Manufacture**: This innovation details a method for manufacturing obicetrapib and its various salts, such as calcium salts. Additionally, it introduces amorphous obicetrapib hemicalcium and new intermediates useful in obicetrapib synthesis, including obicetrapib hydrochloride and a mesylate salt.

Career Highlights

Sheng Cui has amassed a wealth of experience during his career at renowned companies such as Amgen Inc. and Cytokinetics, Inc. His roles at these organizations have allowed him to hone his skills and contribute to pioneering advancements in drug development and formulation.

Collaborations

Throughout his career, Sheng has collaborated with notable professionals, including Henry Morrison and Karthik Nagapudi. These partnerships have fostered a rich environment for innovation and have propelled the progress of various pharmaceutical projects.

Conclusion

With a strong record of patented inventions, Sheng Cui continues to be a pivotal figure in the pharmaceutical industry. His innovative patents not only represent technological advancements but also exhibit his commitment to improving healthcare through research and development.

Profile summary based on public USPTO records.